Publications: Dr Michelle Goulart
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al.(2020).
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications
vol. 11,
(1)
Wu Y, Chang YM, Polton G, Stell AJ, Szladovits B, Macfarlane M, Peters LM, Priestnall SL et al.(2020).
Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation. Frontiers in Oncology
vol. 10,
Goulart MR, Hlavaty SI, Chang YM, Polton G, Stell A, Perry J, Wu Y, Sharma E et al.(2019).
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Scientific Reports
vol. 9,
(1)
Wu Y, Chang YM, Stell AJ, Priestnall SL, Sharma E, Goulart MR, Gribben J, Xia D et al.(2019).
Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice. Scientific Reports
vol. 9,
(1)
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al.(2019).
700PSTAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. Annals of Oncology
vol. 30,
(Supplement_5)
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. (2019).
STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. ANNALS OF ONCOLOGY.
vol. 30,
Goulart MR, Watt J, Siddique I, Lawor R, Dowe T, Bhattacharya S, Crnogorac-Jurcevic T, Allavena P et al. (2019).
Abstract 4892: Pentraxin 3: A stromal derived diagnostic biomarker for pancreatic ductal adenocarcinoma. 4892-4892.